Richard Kibbey, MD
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1598704272
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,675 of the $17,874 with a category attached, or 87.7%. Agios Pharmaceuticals, Inc. accounts for 66.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $6,313 and has fallen 94.1% since, to $375 in 2025.
Across 22 payments — averaging $812.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$12K
- Eli Lilly$5K
- Amgen$297
- Novo Nordisk$225
- Corcept Therapeutics$77
Across 3 payments — averaging $88,708 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Agios Pharmaceuticals, Inc.$266K
What the payments were for
- Consulting fees$15,67588%
- Travel & lodging$1,2637%
- Food & beverage$9365%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 12 | $11,922 |
| Eli Lilly | 4 | $5,352 |
| Amgen | 2 | $297 |
| Novo Nordisk | 3 | $225 |
| Corcept Therapeutics | 1 | $77 |
How this compares
$17,874 in reported general payments places this provider in the 85th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in New Haven
- Ania JastreboffNew Haven$536K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Gerald ShulmanNew Haven$194K
- Karl InsognaNew Haven$68K
- Clemens BergwitzNew Haven$31K
- Peter TebbenNew Haven$17K
- Surani FernandoNew Haven$13K
- Irina RosewaterNew Haven$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.